Skip to content
Screener

Novavax NVAX PP&E (Net)

PP&E (Net) at other companies

Moderna logo
ModernaMRNA
$2.06B-5.1%
Vaxcyte, Inc. logo
Vaxcyte, Inc.PCVX
$260.7M+20.1%
Merck & Co. logo
Merck & Co.MRK
$25.74B+2.0%
ALN
Alnylam PharmaceuticalsALNY
$554.14M+10.9%
Roivant Sciences logo
Roivant SciencesROIV
$11.32M-23.8%
Gilead Sciences logo
Gilead SciencesGILD
$5.83B+6.9%

Segments

By geography

See full
United States$60.68M

Other financials

Income statement

See full
Revenue$56.7M-76.3%
Gross profit$42.5M-81.0%
Operating income-$54.9M-154%
Net income-$53.4M-150%
EPS (diluted)-$0.32-152%

Balance sheet

See full
Cash & equivalents$191.5M-24.5%
Total debt$297.3M+413%
Total equity-$190.7M-607%
Total assets$955.6M-28.5%

Cash flow

See full
Operating cash flow-$72.8M+42.9%
CapEx$588.0K+11.6%
Free cash flow-$73.4M+42.7%

Valuation

See full
Market cap$1.27B+0.5%
Enterprise value$1.38B+27.9%
P/S3.1×+1.9×

Profitability

See full
Gross margin78.6%-9.6pp
Operating margin-56.6%-89.2pp
Net margin-59.9%-99.1pp
FCF margin-59%-61.5pp

Returns & leverage

See full
Return on equity-238.6%
Debt / equity1.5×
Current ratio2.3×0.0×

Where this comes from

Reported directly by Novavax in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The source filing: Novavax’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:50 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001000694-26-000018
Line itemJune 30,2026December 31,2025
Prepaid expenses and other current assets23,01326,815
Assets held for sale87,510
Total current assets771,098978,276
Property and equipment, net38,13344,800
Right-of-use asset, net19,84222,897
Goodwill112,542113,462
Other non-current assets13,96017,077
Total assets$955,575$1,176,512

Item 1. Consolidated Financial Statements

FAQ

What is Novavax's PP&E (net)?
Novavax (NVAX) reported PP&E (net) of $38.13M in Q2 2026.
How has Novavax's PP&E (net) changed year-over-year?
Novavax's PP&E (net) decreased by 70.6% year-over-year, from $129.64M to $38.13M.
What is the long-term trend for Novavax's PP&E (net)?
Over 5 years (2020 to 2025), Novavax's PP&E (net) has grown at a -24.3% compound annual growth rate (CAGR), from $179.95M to $44.8M.
What does PP&E (net) mean?
Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.

Ask your AI about Novavax's pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude